Objective: Osteoradionecrosis (ORN) of the sphenoid is a rare but potentially lethal complication that can occur after irradiation of nasopharyngeal and clival malignancies.
| INTRODUCTION
Radiotherapy is a cornerstone of treatment for the management of nasopharyngeal and skull base malignancies. It is used either alone or in combination with surgery. Osteoradionecrosis (ORN) is a severe complication following radiation therapy. There are relatively few studies on sphenoid ORN but it appears to be a life-threatening condition, with reported survival rates as low as 33%. 1 Several treatment regimen have been described, including conservative management with antibiotherapy or hyperbaric oxygen and more aggressive approaches such as surgical debridement of the necrotic tissues followed by protection of the exposed bone by local or free flaps. 2, 3 However, the extent of ORN may be very variable, and it seems difficult to use a single approach for the management of the various stages of the disease.
The aim of this study was to report on a series of seven patients treated by a combination of medical therapy, endovascular treatment, and/or surgery, with a strategy discussed on a case by case basis and tailored to the symptoms and to the extent of the ORN.
| MATERIALS AND METHODS

| Ethical considerations
In accordance with French laws, the study was approved by the CNIL (Commission Nationale Informatique et Libertés-authorization number 2213218), and all patients gave their informed consent.
| Study design and patients selection
This was a retrospective monocentric study performed in a tertiary skull base center. Patients treated for a skull base ORN from January 2014 to August 2018 were identified from a local database and charts were retrospectively reviewed for the following data: demographics, histologic tumor type, previous treatments of the tumor, clinical signs at presentation, radiological data, treatment, and outcomes. The diagnosis of sphenoid ORN was based on the presence of a bone lysis on
Computed Tomography (CT) within the field of irradiation, with a biopsy ruling out tumor recurrence. In all cases, the patients underwent both CT and Magnetic Resonance Imaging (MRI).
| Treatment strategy
The treatment strategy was discussed on a case by case basis by a mul- advocated in patients presenting with active bleeding or when the internal carotid artery (ICA) was considered at-risk for rupture (irregular shape of the lumen of the artery, the presence of a pseudo-aneurism, ICA no longer covered by bone, and exposed to necrotic soft tissues); in these patients, angiography was performed under general anesthesia, and a balloon test occlusion (BTO) of the ICA was performed. If the test was well tolerated, the ICA was occluded using coils. If the ICA occlusion could not be performed (negative BTO or previous occlusion of the contralateral ICA), a covered stent was used to protect the ICA. Surgery was advocated in symptomatic cases with major bone exposure on endoscopy. In such cases, endoscopic surgical treatment was performed under general anesthesia (after ICA occlusion if necessary) with a maximum drilling of the exposed bone, and covering of the surgical area by a local flap. In this situation, the pedicled temporoparietal fascia flap (TPFF) was the first option. 5 Clinical follow-up was then scheduled at least every 3 months for the first 2 years, and imaging by CT-scan and/or MRI was performed at least every 6 months for the first 2 years.
| RESULTS
Seven patients were included in this study. Clinical and radiological data, treatments, and outcomes are summarized in Table 1 . Mean age at diagnosis was 54 and the sex ratio was 1.3. The patients had been previously treated for nasopharyngeal carcinoma (n = 4, 57%), chordoma (n = 2, 29%), and olfactory neuroblastoma (n = 1, 14%).
They had received 1, 2, or 3 courses of radiotherapy (n = 4, n = 2, and n = 1, respectively). The mean delay between the last course of radio- 
| DISCUSSION
In this study, we describe the results of a multimodal treatment strategy for the management of sphenoid ORN. By applying this strategy, the overall survival rate at 24 months was 57% (or 67% after exclusion of a patient who refused the surgical part of the treatment).
There is relatively few data on sphenoid ORN. An estimated incidence rate of 1% has been reported after radiotherapy for nasopharyngeal carcinoma. 6 However, the incidence may be underestimated because the clinical signs are often not specific. Indeed, some patients present with acute signs such as massive bleeding or meningitis, but in other cases the only presenting signs are asthenia, chronic pain, or even cachexia. 3, 6, 7 Such signs in a patient previously treated by radiotherapy should therefore prompt the clinician to look for ORN. These aspecific sign also explain why many patients are diagnosed at an advanced stage: four out seven patients (57%) presented with an ICA no longer covered by bone, and exposed to necrotic tissues.
The best treatment protocol for sphenoid ORN still remains to be determined. An overall survival rate of 54% has been reported by Liu et al with a surgical management through an endoscopic approach. the use of nasoseptal flap in sphenoid ORN, 9 the risk of necrosis of the flap is, at least in our experience, much higher in previously irradiated patients. The TPFF has other advantages: it may be harvested on both sides, depending on the previous irradiation fields; it is easy to handle and it can cover a wide surface of exposed bone. 5 It also obviates the need for a free flap, which may be more complex to use in previously irradiated patients, especially in this area. 10 One patient was treated conservatively with a purely medical treatment. This patient had no symptom, but endoscopy and CT scan revealed a limited ORN of the sphenoid that extended to C1. The patient received a prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO), a protocol previously described by Delanian et al: this triple-drug therapy has been designed to reduce radio-induced fibrosis and bone destruction and to stimulate osteogenesis via the antioxidant pathway. 4 It has proved effective in mandibular ORN. To the best of our knowledge, this is the first published case of sphenoid ORN successfully treated by PENTOCLO. This encouraging result supports the rationale for a conservative approach in limited cases of sphenoid ORN.
The high mortality rate of sphenoid ORN raises the question of the potential morbidity of radiotherapy for tumors involving the sphenoid. Most authors agree that the risk of severe complications raises significantly in patients who received more than 1 course of radiotherapy, or doses >72 Gy. 6 In this study, the two patients who accepted the treatment plan but died after progression of the ORN had received 130 and 202 Gy. The indication of re-irradiation in residual or recurrent tumor should therefore be carefully discussed. For nasopharyngeal carcinoma, it has been shown that surgery was superior to intensity-modulated radiation therapy in selected cases of rT1-T3
tumors. 11 This new data has been incorporated into the United Kingdom National Multidisciplinary Guidelines in 2016, which state that "surgery in form of nasopharyngectomy should be considered as a first line treatment of residual or recurrent disease at the primary site.". 12 
| CONCLUSION
This retrospective study describes the results of a management strategy adapted to the extent of the disease in sphenoid ORN and based on medical therapy only, or on a combination of medical therapy, interventional radiology, and/or surgery.
